With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...

Teva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived ...

Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would ...

Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other ...

AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning ...

Lisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with ...

Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for ...

Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its ...

The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival ...

Thanks in part to the revolution cell therapy brought to treating blood cancers, the modality is now showing promise in some ...

AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin ...

Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex ...